


Donor 2782

Genetic Testing Summary



Last Updated: 03/21/24

Donor Reported Ancestry: English, French, German


Jewish Ancestry: No

Genetic Test*	Result	Comments/Donor's Residual Risk**

Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/ and a-/a-) and other hemoglobinopathies
Cystic Fibrosis (CF) carrier screening	Negative by genotyping of 99 mutations in the CFTR gene	1/310
Spinal Muscular Atrophy (SMA) carrier screening	Negative for deletions of exon 7 in the SMN1 gene	1/700
Hb Beta Chain-Related Hemoglobinopathy (including Beta Thalassemia and Sickle Cell Disease) by genotyping	Negative for 28 mutations tested in the HBB gene	Beta Thalassenmia: 1/500 Sickle Cell Disease: <1/500

*No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.

**Donor residual risk is the chance the donor is still a carrier after testing negative.



Counsyl Test Results (Egg or Sperm Donor)

Panel: Fairfax Cryobank Fundamental Panel

The Counsyl test uses targeted DNA mutation analysis to simultaneously determine the carrier status of an individual for a number of Mendelian diseases. This report indicates which mutations, if any, were detected for each mutation panel. Because only select mutations are tested, the percentage of carriers detected varies by ethnicity. A negative test result does not eliminate the possibility that the individual is a carrier. Interpretation is given as an estimate of the risk of conceiving a child affected with a disease, which is based on reported ethnicity, the test results, and an assumption of no family history.*



DONOR 2782

DONOR 2782's DNA test shows that he is not a carrier of any disease-causing mutation tested.



Partner

The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

Reproductive Risk Summary

No increased reproductive risks to highlight. Please refer to the following pages for detailed information about the results.

Clinical notes:

Individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies and may also benefit from carrier testing by CBC and hemoglobin electrophoresis or HPLC. ACOG Practice Bulletin No. 78. Obstet Gynecol 2007;109:229-37.

To schedule a free appointment to speak with a genetic counselor about your results, please visit www.counsyl.com/appointment.

*Limitations: In an unknown number of cases, nearby genetic variants may interfere with mutation detection. Other possible sources of diagnostic error include sample mix-up, trace contamination, and technical errors. The reproductive risk summary is provided as an aid to genetic counseling. Inaccurate reporting of ethnicity may cause errors in risk calculation.

This test was developed and its performance characteristics determined by Counsyl, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CEIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's workup; CLIA Number; #05D1102604. Lab Directors: Jessica Jacobson, MD, William K. Seltzer; PhD, FACMG.



Male

Name: DONOR 2782 DOB: Female Not tested

Full Results

Below are the full test results for all diseases on the panel. Noted are the specific genetic mutations for which the patient tested positive or negative. If there was insufficient data to determine the genotype for any variant, this will be noted as "no call." Also listed in this section is the patient's post-test risk of being a carrier of each disease as well as the odds that his future children could inherit each disease.

Beta Thalassemia	Reproductive risk: Less than 1 in 1,000,000	Risk before testing: 1 in 250,000	Reduced risk
DONOR 2782: No mutations detected. This does not rule out the possib assuming a negative family history, is 1 in 1,500. 83% detection rate.	ility of being a carrier of untested m	nutations. The post-test risk of I	being a carrier,
Gone: HBB. Variants (27): K17X, Q39X, Phe41ts, Ser9ts, IVS-II-654, IVS-II-745, IVS-II-8 IVS-II-849(A>G), Gly24 T>A, -87C>G, Hb C, W15X, Gly16ts, Glu6ts, Hb E, Hb D-Punjab,	50, IVS-I-6, IVS-I-110, IVS-I-5, IVS-I-1(G>A НЬ О-Агар.), -88C>T, -28A>G, -29A>G, Lys8fs, P	he711s, IVS-II-849(A>C).
Cystic Fibrosis	-Reproductive risk: 1 in 34,000	Risk before testing: 1 in 3,000	Reduced risk
DONOR 2782: No mutations detected. This does not rule out the possib assuming a negative family history, is 1 in 310. 91% detection rate.	ility of being a carrier of untested m	nutations. The post-test risk of I	being a carrier,
Gene: CFTR. Varlants (99): G85E, R117H, R334W, R347P, A455E, G542X, G551D, R56 1717-1G-A, 1898+1G-A, 2789+5G-A, 3120+1G-A, 3849+10kbC>T, E60X, R75X, E92X, 1078delT, 3876delA, 3905insT, 1812-1G-A, 3272-26A-SQ, 2183AA-SQ, S549R(A>C), R11 K710X, R764X, Q890X, R1066C, W1089X, Y1092X, R1158X, S1196X, W1204X(c.3611G 2043delG, 2055del9-A, 2108delA, 3171delC, 3667del4, 3791delC, 1288insTA, 2184InsA, 1898+5G>T, 3120G>A, 457TAT>G, 3849+4A>G, Q359K/T360K.	, Y122X, G178R, R347H, Q493X, V520F, S 7C, L206W, G330X, T338I, R352Q, S364P, >A), Q1238X, S1251N, S1255X, 3199del6,	549N, P574H, M1101K, D1152H, 2143 G480C, C524X, S549R(T>G), Q552X 574delA, 663delT, 935delA, 936delTA	3delT, 394delTT, 444delA, , A559T, G622D, R709X, , 1677delTA, 1949del84,
Sickle Cell Disease	Reproductive risk: Less than 1 in 1,000,000	Risk before testing: less than 1 in 1,000,000	Reduced risk
DONOR 2782: No mutations detected. This does not rule out the possib assuming a negative family history, is < 1 in 500. 70% detection rate.	ility of being a carrier of untested m	nutations. The post-test risk of l	being a carrier,
Gene: HBB. Varlants (28): Hb S, K17X, Q39X, Phe41fs, Ser9fs, IVS-II-654, IVS-II-745, IV II-849(A>C), IVS-II-849(A>G), Gly24 T>A, -87C>G, Hb C, W15X, Gly16fs, Glu6fs, Hb E, H		1(G>A), -88C>T, -28A>G, -29A>G, Lys	81s, Phe711s, IVS-
Spinal Muscular Atrophy	Reproductive risk: 1 in 97,000	Risk before testing: 1 in 4,800	Reduc <u>o</u> d risk
DONOR 2782: No mutations detected. This does not rule out the possib assuming a negative family history, is 1 in 700, 95% detection rate.	ility of being a carrier of untested n	nutations. The post-test risk of I	being a carrier,

Gene: SMN1. Variants (1): Exon 7 deletion.

This test was developed and its performance characteristics determined by Counsyl, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes, it should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's workup. CLIA Number: #05D1102604. Lab Directore: Jassica Jacobson, MD, William K: Selizer, PhD, FACMG.

	()			7	1	
		GENETICS Instit		F		
		Cytogenet	tic Repo	(ort	A Call	H 2- 13 12
Client Fair	rfax Cryobank -					Process .
Address						
	- 					
Reporting Phone #	12	Fax #	4	Ema	ail	
Patient name/Donor Alias	Donor # 2782			Patient DOB	N/A	
Donor #	0700				D 1 1	Diand
	2782			Specimen type	Peripheral	Blood
Collection Date			2	Specimen type Accession #	Peripheral	
	12/02/2011					
Collection Date	12/02/2011	RESUI				
Collection Date Date Received	12/02/2011				FISH	
Collection Date Date Received CYTOO	12/02/2011 12/02/2011					l
Collection Date Date Received CYTOC Cells counted	12/02/2011 12/02/2011 GENETIC ANALY	SIS	LTS	Accession #	FISH Probe(s)	N/A
Collection Date Date Received CYTOO Cells counted Cells analyzed	12/02/2011 12/02/2011 GENETIC ANALY 50	SIS Type of banding	L TS GTG	Accession #	FISH	N/A
Collection Date Date Received CYTOC Cells counted Cells analyzed Cells karyotyped	12/02/2011 12/02/2011 GENETIC ANALY 50 5	SIS Type of banding	L TS GTG	Accession #	FISH Probe(s)	N/A

INTERPRETATION

Normal male karyotype

No clonal numerical or structural abnormalities were identified. This normal cytogenetic result does not exclude the possibility of the presence of subtle rearrangements beyond the technical limits of detection with this test.


Comments

Wayne S. Stanley, Ph.D., FACMG


Wayne S. Stanley, Ph.D., FACMG Clinical Cytogeneticist


12/15/11 Date


Patient name: DONOR #2782



46,XY







		1 ²				
н			PATIENT INFORMATION 2782, DONOR	[REPORT STATUS Final	
QUEST DIAGNOST	ICS INCORPORATED				ORDERING PHYSICIAN	
CLIENT SERVICE	410.247.9100		DOB: GENDER: M	Age:	CLIENT INFORMATION	
SPECIMEN INFOR	MATION					
SPECIMEN:			ID: 2782		FAIRFAX CRYOBANK	
REQUISITION	: -					
LAB REF NO:						12
COLLECTED : RECEIVED : REPORTED ;	12/02/2011 12/02/2011 12/06/2011	00:00 22:36 10:33		NHR 3120		

Test Name	In Range Out of Range	Reference Range	Lab
CHOLESTEROL, TOTAL* CHOLESTEROL	185	125-200 MG/DL	QBA
AST			OBA
AST	21	10-40 U/L	QВА
ALT			077
ALT	23	9-60 U/L	QBA
		5 00 0, 2	
CBC (INCLUDES DIFF-PLT)			QBA
WHITE BLOOD CELL COUNT	4.9	3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	4.74	4.20-5.80 Million/uL	
HEMOGLOBIN	14.7	13.2-17.1 g/dL	
HEMATOCRIT	43.9	38.5-50.0 %	
MCV	93	80-100 fL	
MCH	30.9	27-33 pg	
MCHC	33.4	32-36 g/dL	
PLATELET COUNT	178	140-400 Thousand/uL	
RDW	13.2	11.0-15.0 %	
MPV	8.6	7.5-11.5 fL	
ABSOLUTE NEUTROPHILS	2935	1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	1308	850-3900 cells/uL	
ABSOLUTE MONOCYTES	446	200-950 cells/uL	
ABSOLUTE EOSINOPHILS	176	15-500 cells/uL	
ABSOLUTE BASOPHILS	34	0-200 cells/uL	
NEUTROPHILS	59.9		
LYMPHOCYTES	26.7	8	
REACTIVE LYMPHOCYTES	0.0	े भू	
MONOCYTES	9.1	ି ବ	
EOSINOPHILS	3.6	0 0 0	
BASOPHILS	0.7	0 00	
COMMENT	0.7	U	
HEMOGLOBINOPATHY EVALUATION			OBA
RED BLOOD CELL COUNT	4.74	4.20-5.80 Million/uL	~ -
HEMOGLOBIN	14.7	13.2-17.1 g/dL	
HEMATOCRIT	43.9	38,5-50.0 %	
MCV	93	80-100 fL	
MCH	30.9	27-33 pg	
RDW	13.2	11.0-15.0 %	
HEMOGLOBIN A	97.7	>96.0 %	
HEMOGLOBIN F	NONE DETECTED	0.0-1.9	
	2,3	1.8-3.5 %	
HEMOGLOBIN A2	4.3	T.0-2.2 @	
HGB SCREEN INTERPRETATION			
	THE HEMOGLOBINOPATHY SCRE	EN IS NORMAL.	643

	([*]	Ē,
51	PATIENT INFORMATION 2782, DONOR	REPORT STATUS Final
QUEST DIAGNOSTICS INCORPORATED		ORDERING PHYSICIAN
COLLECTED: 12/02/2011 00:00 REPORTED: 12/06/2011 10:33	DOB: Age: Age: GENDER: M ID: 2782	
Test Name	In Range Out of Range	Reference Range Lab
HEMOGLOBINOPATHY EVALUATION ABNORMAL HEMOGLOBIN #1 %:	(Continued) 0.0	8

Performing Laboratory Information:

1

QBA Quest Diagnostics Incorporated 1901 Sulphur Spring Road Baltimore MD 21227 Laboratory Director: Robert R. L. Smith, M.D.